To use all functions of this page, please activate cookies in your browser.
My watch list
my.chemeurope.com
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Northwest Biotherapeutics
Northwest Biotherapeutics is an American pharmaceutical company that focuses on developing immunotherapies against different types of cancer. Additional recommended knowledge
MissionNWBT's stated goals stress product quality and purity, innovation, and efficient production.[3] TechnologyThe DCVax® technology upon which NWBT's therapies rely involves injecting cancer patients with dendritic cells, which contain high levels of the same antigens found in tumor cells. The immune system, alerted by these antigens, attacks the cancer as well as the injected cells. ProductsDCVax® Brain, the first vaccine against brain cancer approved by the American Food and Drug Administration (FDA), is set to be distributed at select centers in Switzerland by September 2007.[1] DCVax® Prostate has also been approved by the FDA for trials.[4] Footnotes and references
NWBT NASDAQ: {{{1}}}
|
|||||||||||||||||
| This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Northwest_Biotherapeutics". A list of authors is available in Wikipedia. | |||||||||||||||||
